Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: Response and correction of immunological anomalies

Current Pharmaceutical Design

Volumn 19, Issue 27, 2013, Pages 4893-4899

  Li, Xiao Yan ^a   Zheng, Zhao Hui ^b   Li, Xue Yi ^b   Guo, Jian ^a   Zhang, Yan ^a   Li, Hui ^a   Wang, Yang Wei ^a   Ren, Jun ^c   Wu, Zhen Biao ^b  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

Diabetes; Foot; Inflammatory; Mesenchymal stem cells; RegulatoryT cells; Type

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 17; INTERLEUKIN 6; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; DIABETIC FOOT; DIABETIC PATIENT; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INJECTION SITE PAIN; INSULIN TREATMENT; LIMB WEAKNESS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXYGEN TENSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SKIN TEMPERATURE; TH1 CELL; TH17 CELL; UMBILICAL CORD BLOOD;

ADULT; AGED; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; DRUG MONITORING; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAMUSCULAR; INSULIN; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; THIGH;

EID: 84881345199     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990326     Document Type: Article

References (46)

1. Weck M, Slesaczeck T, Rietzsch H, et al. Noninvasive management of the diabetic foot with critical limb ischemia: current options and future perspectives. Therapeut Adv Endocrinol Metabol 2011; 2: 247-55.
2. Moura Neto A, Zantut-Wittmann DE, Fernandes TD, Nery M, Parisi MC. Risk factors for ulceration and amputation in diabetic foot: study in a cohort of 496 patients. Endocrine 2012.
3. Dalla Paola L, Faglia E. Treatment of diabetic foot ulcer: an overview strategies for clinical approach. Curr Diabetes Rev 2006; 2: 431-47.
4. Bowling FL, Jude EB, Boulton AJ. MRSA and diabetic foot wounds: contaminating or infecting organisms? Curr Diab Rep 2009; 9: 440-4.
5. Akita S, Yoshimoto H, Akino K, et al. Early experiences with stem cells in treating chronic wounds. Clinics Plastic Surgery 2012; 39: 281-92.
6. Lee SH, Lee JH, Cho KH. Effects of Human Adipose-derived Stem Cells on Cutaneous Wound Healing in Nude Mice. Annals Dermatol 2011; 23: 150-5.
7. Tang J, Xie Q, Pan G, Wang J, Wang M. Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg 2006; 30: 353-61.
8. Honma T, Honmou O, Iihoshi S, et al. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 2006; 199: 56-66.
9. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg 2003; 75: 204-9.
10. Chen SL, Fang WW, Qian J, et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117: 1443-8.
11. Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010; 3: 248-69.
12. Rogers I, Casper RF. Umbilical cord blood stem cells. Best Pract Res Clin Obstet Gynaecol 2004; 18: 893-908.
13. Barker JN, Wagner JE. Umbilical cord blood transplantation: current practice and future innovations. Crit Rev Oncol Hematol 2003; 48: 35-43.
14. Gang EJ, Jeong JA, Hong SH, et al. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells 2004; 22: 617-24.
15. Hanson S, Thibeault SL, Hematti P. Clinical applications of mesenchymal stem cells in laryngotracheal reconstruction. Curr Stem Cell Res Ther 2010; 5: 268-72.
16. Anzalone R, Lo Iacono M, Loria T, et al. Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev 2011; 7: 342-63.
17. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28: 2155-60.
18. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008; 57: 1759-67.
19. Boumaza I, Srinivasan S, Witt WT, et al. Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 2009; 32: 33-42.
20. Zeng C, Shi X, Zhang B, et al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) 2012; 90: 175-86.
21. Bianchi C, Penno G, Pancani F, et al. Non-traditional cardiovascular risk factors contribute to peripheral arterial disease in patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 78: 246-53.
22. Maderal AD, Vivas AC, Zwick TG, Kirsner RS. Diabetic foot ulcers: evaluation and management. Hospital practice 2012; 40: 102-15.
23. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
24. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
25. Fujimoto M, Nakano M, Terabe F, et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol 2011; 186: 32-40.
26. Arien-Zakay H, Lazarovici P, Nagler A. Tissue regeneration potential in human umbilical cord blood. Best Pract Res Clin Haematol 2010; 23: 291-303.
27. Reddi AS, Kuppasani K, Ende N. Human umbilical cord blood as an emerging stem cell therapy for diabetes mellitus. Curr Stem Cell Res Ther 2010; 5: 356-61.
28. Wang HS, Shyu JF, Shen WS, et al. Transplantation of insulinproducing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice. Cell Transplant 2011; 20: 455-66.
29. Phuc PV, Nhung TH, Loan DT, Chung DC, Ngoc PK. Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. In vitro Cell Dev Biol Anim 2011; 47: 54-63.
30. Jiang R, Han Z, Zhuo G, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med 2011; 5: 94-100.
31. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-43.
32. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.
33. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature immunology 2003; 4: 330-6.
34. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006; 103: 6659-64.
35. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nature Immunol 2007; 8: 191-7.
36. Lawson JM, Tremble J, Dayan C, et al. Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clinical Exp Immunol 2008; 154: 353-9.
37. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003; 101: 2999-3001.
38. Liu G, Ma H, Qiu L, et al. Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol 2011; 89: 130-42.
39. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007; 104: 19446-51.
40. Lopes-Virella MF, Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci 2003; 8: s750-68.
41. Westcott DJ, Delproposto JB, Geletka LM, et al. MGL1 promotes adipose tissue inflammation and insulin resistance by regulating 7/4hi monocytes in obesity. J Exp Med 2009; 206: 3143-56.
42. Wueest S, Rapold RA, Schumann DM, et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 2010; 120: 191-202.
43. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-23.
44. Wu KH, Zhou B, Lu SH, et al. In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J Cell Biochem 2007; 100: 608-16.
45. Iwase T, Nagaya N, Fujii T, et al. Comparison of angiogenic potency between mesenchymal stem cells and mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc Res 2005; 66: 543-51.
46. Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes 2004; 53: 861-4.